MedPath

Acerand Therapeutics (Shanghai) Limited

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor, Adult
BRCA1 Mutation
BRCA2 Mutation
Ovarian Cancer
Breast Cancer
Prostate Cancer
Interventions
First Posted Date
2024-04-24
Last Posted Date
2025-05-18
Lead Sponsor
Acerand Therapeutics (Shanghai) Limited
Target Recruit Count
298
Registration Number
NCT06380660
Locations
🇨🇳

Chongqing Cancer Hospital, Chongqing, Chongqing, China

🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

Jinan Central Hospital, Jinan, Shandong, China

and more 10 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.